:: Main :: About :: Current Issue :: Archive :: Submit :: Contact ::
:: Volume 3, Issue 2 And 3 (8-2016) ::
vacres 2016, 3(2 And 3): 64-68 Back to browse issues page
Preparation and in vivo anti-tumor evaluation of human papillomavirus E7 adjuvanted with Montanide ISA 266 as a vaccine candidate
M Mashhadi Abolghasem Shirazi , F Roohvand , A Arashkia *
Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.
Abstract:   (894 Views)
Introduction: Human papillomavirus (HPV) 16 E7 protein is expressed constitutively by HPV-infected tumor cells. Mutant versions of E7 are considered as safer candidates for immunotherapy of cervical cancer.  Different strategies including formulation with adjuvants are used to induce a potent immune response against antigenic proteins. Methods: In this experimental study, we used Escherichia coli as a host to recombinantly express wild-type E7 and its mutant non-oncogenic form as E7GGG. We formulated both antigens with Montanide ISA 266 adjuvant and evaluated IFN-γ and IL-4 cytokines and antibody levels and also tumor regression in tumor-harboring C57BL/6 mice. Results: It was demonstrated that formulation of E7 and E7GGG antigens with Montanide ISA 266 resulted in a Th2-biased immune response. In the therapeutic mouse model, these formulations resulted in significant tumor regression compared to the control group. Conclusion: The formulation of the wild-type E7 and mutant E7GGG with Montanide ISA 266 might not be an optimal approach to regress TC-1 induced tumor; however, such combinations might be considered as an additive approach for stimulating the immune responses.
Keywords: Human Papillomavirus 16, E7 Oncogene, Protein Vaccine.
Full-Text [PDF 517 kb]   (219 Downloads)    
Type of Study: Original article |
Received: 2017/12/12 | Accepted: 2017/12/12 | Published: 2017/12/12
Add your comments about this article
Your username or Email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mashhadi Abolghasem Shirazi M, Roohvand F, Arashkia A. Preparation and in vivo anti-tumor evaluation of human papillomavirus E7 adjuvanted with Montanide ISA 266 as a vaccine candidate. vacres. 2016; 3 (2 and 3) :64-68
URL: http://vacres.pasteur.ac.ir/article-1-105-en.html


Volume 3, Issue 2 And 3 (8-2016) Back to browse issues page
تحقیقات واکسن Vaccine Research
Persian site map - English site map - Created in 0.12 seconds with 30 queries by YEKTAWEB 3647